Soberana 02 and Soberana Plus, two of the Cuban drugs developed by the Finlay Institute of Vaccines (IFV) against COVID-19, received this Friday the Grand Prize of the international business event “Leader of the Year”, in Belarus, where its social impact and its contribution to the global fight against the pandemic.
Santiago Pérez, ambassador of the Island in Minsk, said to Prensa Latina that Cuban vaccines have safety and immunogenicity results in the pediatric, adult and elderly population, the main reason why they were awarded according to the criteria of a Council of Experts, made up of representatives of business communities, ministries, relevant departments and public organizations of Belarus.
According to the report itself, this award also highlights the work of three institutions such as the IFV, the Center for Molecular Immunology and the National Center for Biopreparations, which form a long-term strategic alliance in Cuban scientific development, said Idania Caballero, director of the representative office of the BioCubaFarma Business Group for the countries of the Eurasian Union.
#Last News
get the shots #Sovereign02 Y #SoberanaPlus of #Cuba the Grand Prize of the organization “Leader of the Year” in #Belarus for his contribution to the global fight against #COVID19.
Thank you and congratulations to all who have contributed to the achievement of this Award.
?? pic.twitter.com/btfPN5HuUg– Finlay Vaccine Institute (@FinlayInstituto) December 9, 2022
The novelty of the immunogen innovation and its repercussion in other nations were other aspects that supported the award at the international event in Belarus, where Soberana Plus received the approval of the Center for Expertise and Testing of the Ministry of Health at the end of last July for its application against COVID-19.
For its part, the regulatory agency of the Eurasian country registered Soberana 02 in October, just when a batch of Soberana Plus arrived in Belarus to support the immunization of the population in the fight against the pandemic.
According to Prensa Latina, the directors of the Finlay Vaccine Institute assured that to date more than 20 million doses have been applied in Cuba, Iran, Venezuela, Nicaragua and Belarus.
